NeoPhore Closes £6M Extension to Series B; Round to £21.5M
- NeoPhore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised £6M in an extension to its Series B funding, now totaling £21.5M
- The investors included CRT Pioneer Fund, Claris Ventures, 2Invest, 3B Future Health Fund and Astellas Venture Management
- The company intends to use the funds to progress its expanding pipeline of drugs, encompassing multiple biological targets and modalities of treatment, to the start of IND-enabling studies in 2024
- The company focuses on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system
- Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer
- The company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers
